Section Review: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Newer immunosuppressive drugs and other agents for the treatment of rheumatoid arthritis - An update

References

• ZVAIFLER NJ: Etiology and pathogenesis of rheumatoidarthritis. In: Arthritis and Allied Conditions. McCarty DJ, Koopman WJ (Eds.). Lea and Febiger, Philadelphia-London (1993). A good chapter on the aetiology and pathogenesis of rheumatoid arthritis.
   Google Scholar
• NEPOM GT, EHRLICH H: MHC class II molecules andautoitnmunity. Ann. Rev. Immunol. (1991) 9:493–525.
   PubMed Web of Science ®Google Scholar
• MCCULLOCH j, LYDYARD PM, ROOK GAW: Rheumatoid arthritis: How well do the theories fit the evidence? din.Exp. Immunol. (1993) 92:1-6. A good brief review on the aetiopathogenesis of rheumatoid arthritis.
   Google Scholar
• SE WELL KL, TRENTHAM DE: Pathogenesis of rheumatoid arthritis. lancet (1993) 341(8840):283–286.
   PubMed Web of Science ®Google Scholar
• CARLSON RP: Newer immunosuppressive drugs and other agents for the treatment of rheumatoid arthritis. Curr. Opin. Invest. Drugs (1993) 2(7):751–762.
   Google Scholar
• PANAY' GS, TUGWELL P: The use of cyclosporin A in rheumatoid arthritis. Br. J. Rheumatol. (1994) 33(10):967–969.
   PubMedGoogle Scholar
• MOLNAR-KIMBER KL, SEHGAL SN: Rapamycin (Si-rolimus, Rapamune): A novel immunosuppressive agent. Kimball E (Ed.). CRC Press. In press.
   Google Scholar
• HARTMAN DA, OCHALSKI SJ, ZIMMERMAN JL, SEHGAL SN,CARLSON RP: Effects of different oral formulations of sirolienus (Rapamycin, Rapamune6) and combination therapy with cyclosporin A in the rat developing adju-vant arthritis model. Abstract from the Seventh Interna-tional Conference of the Inflammation Research Association (1994):106.
   Google Scholar
• SEHGAL SN, H BAKER, C VEZINA: Rapamycin (AY-22,989), a new antifungal antibiotic H. Fermentation, isolation and characterization. J. Antibiot. (1975) 28(10):727–732.
   Google Scholar
• CHEN Y, CHEN H, RHOADS AE, WARNER L, CAGGIANO TJ, FAILLI AHZ, HSIANO CL, NAKANISHI K, MOLNAR-KIMBER KL: A putative sirolimus (rapamycin) effector protein. Biochem. Biophys. Res. Commun. (1994) 203:1–7.
   PubMed Web of Science ®Google Scholar
• CHEN Y, CHEN H, RHOAD A, WARNER LM, CAGGIANO T, FAILLI A, ZHANG H, NAKANISHI K, MOLNAR-KIMBER KL: Isolation of a sirolimus (rapamycin) effector protein. Abstractfrom Seventh International Conference of the Inflam-mation Research Association (1994):W53.
   Google Scholar
• BROWN EJ, ALBERS MW, SHIN TB, ICHIKAWA K, KEITHCT, LANE WS, SCHREIBER SL: A mammalian protein targeted by G-1 arresting rapamycin receptor complex. Nature (1994) 369(6483):756–758.
   PubMed Web of Science ®Google Scholar
• SABATINI DM, ERDJUMENT-BROMAGE H, LUIM, TEMPESTP, SNYDER SH: RAPTI: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORS. Cell (1994) 78(1):35–43.
   PubMed Web of Science ®Google Scholar
• CHIU MI, KATZ H, BERLIN V: RAFT1, a mammalian homolog of yeast TOR, interacts with the FKBP12/ra-pamycin complex. Proc. Natl. Acad. Sci. USA (1994) 92(25):12574–12578.
   Google Scholar
• DAVIES CB, MADDEN RL, ALEXANDER JW, COFER BR, FISHER RA, ANDERSON P: Effect of a short course of rapamycin, cyclosporin A, and donor-specific transfu-sion on rat cardiac allograft survival. Transplantation (1993) 55(5):1107–1112.
   PubMed Web of Science ®Google Scholar
• OCHIAI T, GUNJI Y, NAGATA M, ASANO T, ISONO K: Immunosuppressive effects of rapamycin in experi-mental organ allografting. Transplantation (1993) 56(1):15–19,
   PubMed Web of Science ®Google Scholar
• DUMONT Fj, KASTNER C, IACOVONE F, Jr., FISCHER PA: Quantitative and temporal analysis of the cellular inter-action of FK-506 and rapamycin in T-lymphocytes. J. Pharmacol. Exp. Then (1994) 268(1):32–41.
   PubMed Web of Science ®Google Scholar
• Scrip (1993) 1932:23
   Google Scholar
• Scrip (1994) 1970:23
   Google Scholar
• Pharrnaprojects (May, 1994).
   Google Scholar
• MATTEY DL, EVANS E, DAWES PT: The effects of tenidap on cytokine induced proliferation of human synovial fibroblasts in vitro. Annals Rheum. Dis. (1994) 53(4):250–255.
   PubMed Web of Science ®Google Scholar
• MARTEL-PELLETIER J, OUNISSI H, CLOUTIER JM, POUTER JP: Tenidap effectively reduces cytokine syn-thesis and expression by human rheumatoid arthritis synovium. Arth. Rheum. (1994) 37(Suppl.):S309.
   Google Scholar
• BONDESON j, SUNDLER R: Effects of tenidap on Ca2 -and protein kinase C-mediated protein phosphoryla-don activation of arachidonate-mobilizing phospholi-pase A2 and subsequent eicosanoid formation in macrophages. Btochem. Pharmacol. (1994) 48(6):1171–1179.
   PubMed Web of Science ®Google Scholar
• FDC Reports (The Pink Sheet) (August, 1992):10.
   Google Scholar
• Pharmaprojects (December, 1994).
   Google Scholar
• Pharmaprojects (February, 1995).
   Google Scholar
• MACKENZIE AR, BOLLINGER P, COOPER PH, DEL POZO E, ELFORD P, GRAEBER M, BUGLER HU, LEUTWILER A, PAYNE T, RUCH W, SCHNYDER J, WUETHRICH H-J: Phar-macologic effects of a new antiarrhythmic agent, IX 207–887. Br. J. Rheumatol. (1991) 30\(Suppl. 2):75–78.
   Google Scholar
• DOUGADOS N, COMBE B, BEVERIDGE T, BOURDEIX I, LALLEMAND A, AMOR B, SANY J: IX 207-887 in rheuma-toid arthritis. Arth. Rheum. (1992) 35(9):999–1006.
   PubMedGoogle Scholar
• ERDO F, TOROK K, SZEICELY JL: Measurement of inter-leukin-1 liberation in zymosan air-pouch exudate in mice. Agents Actions (1994) 41(1/2):93–95.
   Google Scholar
• CHERWINSKI HM, MCCARLEY D, SCHATZMAN R, DEVENS **B, RANSOM JT: The in2munosuppressant leflunomideInhibits lymphocyte progression through cell cycle by a novel mechanism. J. Pharmacol. Exp. Ther. (1995) 272(1):460–468. It represents good experimental evidence in detail for the mechanism of action of leflunomide.
   Google Scholar
• ZIELINSKI T, ZEITTER D, MeLLNER S, BARTLETT RR: Le-flunomide, a reversible inhibitor of pyrimidine biosyn-thesis? Abstract from the Seventh International Conference of the Inflammation Research Association (1994):P105.
   Google Scholar
• ZIELINSKI T, HERMANN M, MULLER H-J, REIDEL N, BAR-TLETT RR: The influence of leflunomide on cell cycle IL-2 receptor (IL-2R) and its gene expression. Agents Actions (1994) 41(Special Conference Issue):C204–205.
   Google Scholar
• GIANT TT, MIICECZ K, BRENNAN F, NEGRIOU G, BAR-TLETT RR: Suppression of autokrunune responses and Inflammatory events by leflunomide in an animal model for rheumatoid arthritis. Agents Actions (1994) 41(Special Conference Issue):C267–C270.
   Google Scholar
• NIKCEVICH DA, FINNEGAN A, CHONG A S-F, WILLIAMS JW, BREMER EG: Inhibition of interleukin 2 (IL-2)-stimu-lated tyrosine kinase activity by leflunomide. Agents Actions (1994) 41(Special Conference Issue):C279–C282.
   Google Scholar
• Pharmaprojects (April, 1995).
   Google Scholar
• ALBRIGHTSON CR, BUGELSKI PJ, BERKHOUT TA, JACK-SON B, KERNS WD, ORGAN AJ, BADGER AM: Separation of immunomodulatory and cholesterol lowering activi-ties of heterocyclic azaspiranes. J. Pharm. Exp. Tber. (1995) 272(1):689–698.
   PubMedGoogle Scholar
• BADGER AM, SCHWARTZ DA, PICKER DH, DORMAN JW,BRADLEY PC, CHEESEMAN EN, DIMARTINO MJ, HANNA N, MIRABELLI CK: Antiarthritic and suppressor cell induc-ing activity of azaspiranes: structure-function relation-ships of a novel class of immunomodulatory agents. J Med. Cbem.(1990) 33(11):2963–2970.
   Google Scholar
• BADGER AM, KUPIEC-WEGLINSKI JW: Azaspiranes with therapeutic activity in animal models of autoimmune disease and organ transplantation. New immunosup-pressive modalities in organ transplantation. Kupiec-Weglinski JW (Ed.). RG Landes Company (1994).
   Google Scholar
• BADGER AM, SWIFT BA, BUGELSKI PJ: Suppressor cell (SC) activity induced by the azaspiranes may reside in a non-adherent or semiadherent tissue macrophage population. J. Immunol. (1993) 150(8 part 2):75A. Richard P Carlson, Wyeth-Ayerst Research, CN 8000, Princeton, NJ 08543–8000, USA.
   Google Scholar